Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis
Conclusions About Benefits and Harms (1)
Pubertal and prepubertal patients with CF who were treated with rhGH experienced a modest decrease in the annual rate of hospitalizations. Modest increases in weight were also observed, but while weight is associated with mortality risk, it is unclear if weight change associated with rhGH use modifies risk.
There is no direct evidence to evaluate whether gains in pulmonary function and growth seen upon rhGH treatment will lead to improved survival or other long-term health benefits.
There is insufficient evidence to evaluate harms associated with rhGH treatment, including the risk of CF-related diabetes and cancer.
Keywords: hospitalization | weight | mortality | risk | bone mineral content | BMC | fracture | cystic fibrosis | CF | rhGH | recombinant human growth hormone | human growth hormone | HGH
- Phung OJ, Coleman CI, Baker EL, et al. Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis. AHRQ Comparative Effectiveness Review No. 23 (Prepared by University of Connecticut-Hartford Hospital Evidence-based Practice Center under Contract No. 290-2007-10067-I). Rockville, MD: Agency for Healthcare Research and Quality; October 2010. AHRQ Publication No. 11-EHC003-EF.
Your slide tray is being processed.